For oral communications (including slides of lectures and posters), click here or scroll until after the publications.

See also my Google scholar

Selected contributions



Predicting survival in patients with advanced NSCLC treated with atezolizumab using pre- and on-treatment prognostic biomarkers
S. Benzekry, M. Karlsen, C. Bigarré, A. El Kaoutari, B. Gomes, M. Stern, A. Neubert, R. Bruno, F. Mercier, S. Vatakuti, P. Curle and Candice Jamois.
Clinical Pharmacology and Therapeutics, 116, 1110–1120, medRxiv, 2024


Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial
F. Barlesi, et al., S. Benzekry
Annals of Oncology, 16 (suppl_1), 2022


Artificial intelligence and mechanistic modeling for clinical decision making in oncology
S. Benzekry
Clinical Pharmacology and Therapeutics, Volume 108, Issue 3, pp.471-486, 2020


Mechanistic modeling of metastatic relapse in early breast cancer to investigate the biological impact of prognostic biomarkers
C. Bigarre, F. Bertucci, P. Finetti, G. MacGrogan, X. Muracciole*, S. Benzekry. * = joint senior authors
Computer Methods and Programs in Biomedicine, 231, 107401, hal, 2023


Machine learning and mechanistic modeling for prediction of metastatic relapse in breast cancer
C. Nicolo, C. Perier, M. Prague, G. MacGrogan, O. Saut, S. Benzekry
JCO: Clinical Cancer Informatics, Volume 4, pp. 259-274, bioRxiv, 2020


Contributions in Mathematical Oncology: When Theory Meets Reality
HDR (Habilitation à diriger des recherches) thesis, defended November 13th, 2017


Modeling spontaneous metastasis following surgery: an in vivo-in silico approach
S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi, J.M.L. Ebos
Cancer Research, Volume 76, Issue 3, pp. 535-547, hal, 2016


Mathematical modeling of tumor-tumor distant interactions supports a systemic anti-proliferative control of tumor growth
S. Benzekry, C. Lamont, D. Barbolosi, L. Hlatky, P. Hahnfeldt
Cancer Research, Volume 77, Issue 18, pp.5183-5193, 2017


Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
M. Bilous, C. Serdjebi, A. Boyer, P. Tomasini, C. Pouypoudat, D. Barbolosi, F. Barlesi, F. Chomy and S. Benzekry
Scientific Reports, Volume 9, Issue 1, 13018, bioRxiv, hal, 2019


Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth
S. Benzekry, C. Lamont, A. Beheshti, A. Tracz, J.M.L. Ebos, L. Hlatky, P. Hahnfeldt
PLoS Computational Biology, Volume 10, Issue 8, e1003800, 2014


Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma
D.C. Imbs*, R. El Cheikh*, A. Boyer, J. Ciccolini, C. Mascaux, B. Lacarelle, F. Barlesi, D. Barbolosi and S. Benzekry, * = equal contribution
CPT Pharmacometrics Syst Pharmacol, Volume 7, Issue 1, pp. 42-50, hal, 2018


Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, C. Poignard, J. ML Ebos, S. Benzekry
PLoS Computational Biology, Volume 16, Issue 2, e1007178, bioRxiv, 2020


Computational modelling of metastasis development in renal cell carcinoma
E. Baratchart, S. Benzekry*, A. Bikfalvi*, T. Colin*, L.S. Cooley, R. Pineau, E. Ribot, O. Saut, W. Souleyreau, * = joint supervising authors
PLoS Computational Biology, Volume 11, Issue 11, e1004626, hal, 2015


Journal articles

    2024



  1. Predicting survival in patients with advanced NSCLC treated with atezolizumab using pre- and on-treatment prognostic biomarkers
    S. Benzekry, M. Karlsen, C. Bigarré, A. El Kaoutari, B. Gomes, M. Stern, A. Neubert, R. Bruno, F. Mercier, S. Vatakuti, P. Curle and Candice Jamois.
    Clinical Pharmacology and Therapeutics, 116, 1110–1120 medRxiv, doi.org/10.1002/cpt.3371, 2024

  2. Machine-learning and mechanistic modeling of primary and metastatic breast cancer growth after neoadjuvant targeted therapy
    S. Benzekry, M. Mastri, C. Nicolo, J. ML Ebos
    PLoS Comp Biol, bioRxiv, 2024

  3. A senescence-mimicking (senomimetic) VEGFR TKI side-effect primes tumor immune responses via IFN/STING signaling
    M. Dolan, Y. Shi, M. Mastri, M. D Long, A. McKenery, J. W. Hill, C. Vaghi, S. Benzekry, J. J Barbi and J. M. L. Ebos
    Mol Cancer Ther, 24, 1241–1260 doi:10.1158/1535-7163.mct-24-0139, 2024

  4. Computational markers for personalized prediction of outcomes in non-small cell lung cancer patients with brain metastases
    S. Benzekry*, P. Schlicke*, P. Tomasini, E. Simon. * = joint first authors
    Clin Exp Metastasis, 41(1):55-68, medRxiv, 2024

  5. Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma
    K. Atsou, A. Auperin, J. Guigay, S. Salas, S. Benzekry
    accepted in CPT Pharmacometrics Syst Pharmacol, hal, 2024

  6. Computational modeling for circulating cell-free DNA in clinical oncology
    L. Nguyen-Phuong, S. Salas, S. Benzekry
    accepted in JCO: Clin Cancer Informatics, hal 2024

  7. Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells
    Y. Shi, M. Dolan, M. Mastri, J. W. Hill, A. Dommer, S. Benzekry, K. Eng, J. ML Ebos
    EMBO Reports, bioRxiv, 2024

  8. Role of PCI for patients with extensive stage small cell lung cancer in the immunotherapy era: real-life data report over the period 2014 to 2021.
    A. Daumas, C. Bigarre, M. Boucekine, A. Zaccariotto, A. Mogenet, E. Gouton, J. Pluvy, P. Tomasini, X. Muracciole, S. Benzekry, L. Greillier and L. Padovani
    accepted in Cancers, 2024


    9. 2023


  9. Mechanistic modeling of metastatic relapse in early breast cancer to investigate the biological impact of prognostic biomarkers
    C. Bigarre, F. Bertucci, P. Finetti, G. MacGrogan, X. Muracciole*, S. Benzekry. * = joint senior authors
    Computer Methods and Programs in Biomedicine, 231, 107401, hal, 2023

  10. Reuniting Philosophy and Science to Advance Cancer Research
    T. Pradeu,... S. Benzekry,..., L. Laplane
    Biological Reviews, 2023

  11. Une comparaison des algorithmes d'apprentissage pour la survie avec données manquantes
    P. Dufossé, S. Benzekry
    arXiv, 2023


    12. 2022


  12. Practical identifiability analysis of a mechanistic model for the time to distant metastatic relapse and its application to renal cell carcinoma
    A. Alvarez-Arenas, W. Souleyreau, A. Emanuelli, L.S. Cooley, JC Bernhard, A. Bikfalvi, and S. Benzekry
    PLoS Computational Biology, 18(8): e1010444, 2022

  13. Tumor growth monitoring in breast cancer xenografts: a good technique for a strong ethic
    A. Rodallec, C. Vaghi, J. Ciccolini, R. Fanciullino, and S. Benzekry
    PLoS One, 17(9): e0274886, 2022

  14. Des modèles mathématiques pour la recherche clinique en cancérologie
    S. Benzekry
    Interstices, 2022

  15. Macro-scale models for fluid flow in tumour tissues: impact of microstructure properties
    C. Vaghi, R. Fanciullino, S. Benzekry, C. Poignard
    Journal of Mathematical Biology, Volume 84, Issue 27, bioRxiv, 2022

  16. Asymptotic analysis of a biphase tumor fluid flow: the weak coupling case
    C. Vaghi, S. Benzekry, C. Poignard
    Appl Math Comput, Volume 413, 126635, 2022


    17. 2021


  17. Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data
    S. Benzekry, M. Grangeon, M. Karlsen, M. Alexa, I. Bicalho-Frazeto, S. Chaleat, P. Tomasini, D. Barbolosi, F. Barlesi, L. Greillier
    Cancers, Volume 5, pp. 81-90, medRxiv, 2021

  18. Development and Validation of a Prediction Model of Overall Survival in High-Risk Neuroblastoma Using Mechanistic Modeling of Metastasis
    S. Benzekry, C. Sentis, C. Coze, L. Tessonnier, N. André
    JCO: Clin Cancer Informatics, Volume 5, pp. 81-90, medRxiv, 2021

  19. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression
    L. Cooley, J. Rudewicz, W. Souleyreau, A. Emmanuelli, A. Alvarez-Arenas, K. Clarke, F. Falciani, M. Dufies, D. Lambrechts, E. Modave, D. Chalopin-Fillot, R. Pineau, D. Ambrosetti, J-C Bernhard, A. Ravaud, S. Negrier, J-M Ferrero, G. Pages, S. Benzekry, M. Nikolski, A. Bikfalvi
    Molecular Cancer, 20, bioRxiv, 2021


    20. 2020



  20. Artificial intelligence and mechanistic modeling for clinical decision making in oncology
    S. Benzekry
    Clinical Pharmacology and Therapeutics, Volume 108, Issue 3, pp.471-486, 2020

  21. Machine learning and mechanistic modeling for prediction of metastatic relapse in breast cancer
    C. Nicolo, C. Perier, M. Prague, G. MacGrogan, O. Saut, S. Benzekry
    JCO: Clinical Cancer Informatics, Volume 4, pp. 259-274, bioRxiv, 2020

  22. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
    C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, C. Poignard, J. ML Ebos, S. Benzekry
    PLoS Computational Biology, Volume 16, Issue 2, e1007178, bioRxiv, 2020

  23. Mechanistic learning for combinatorial strategies with immuno-oncology drugs: can model-informed designs help investigators?
    J. Ciccolini, D. Barbolosi, N. André, F. Barlesi, S. Benzekry
    JCO: Precision Oncology, , Volume 4, pp. 486-491, 2020


    24. 2019



  24. Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
    M. Bilous, C. Serdjebi, A. Boyer, P. Tomasini, C. Pouypoudat, D. Barbolosi, F. Barlesi, F. Chomy and S. Benzekry
    Scientific Reports, Volume 9, Issue 1, 13018, bioRxiv, hal, 2019

  25. Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology
    A. Rodallec, R. Fanciullino, S. Benzekry, J. Ciccolini, EORTC PAMM group
    Anticancer Research, Volume 39, Issue 7, p. 3419-3422, hal, 2019

  26. Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non-Small Cell Lung Cancer
    B. K Schneider, A. Boyer, J. Ciccolini, F. Barlesi, K. Wang, S. Benzekry* and J. P Mochel*, * = joint senior authors
    CPT Pharmacometrics Syst Pharmacol, Volume 25, hal, 2019

  27. CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
    J. P Mochel, S. C Ekker, C. M Johannes, A. E Jergens, K. Allenspach, A. Bourgois-Mochel, M. Knouse, S. Benzekry, W. Wierson, A. K LeBlanc, S. S Kenderian
    AAPS J, Volume 21, Issue 3, p.50, hal, 2019


    28. 2018



  28. Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
    A. Rodallec, G. Sicard, R. Fanciullino, S. Benzekry, B. Lacarelle, G. Milano, J. Ciccolini
    Expert Opin Drug Met, Volume 14, Issue 11, p. 1139-1147, 2018

  29. Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma
    D.C. Imbs*, R. El Cheikh*, A. Boyer, J. Ciccolini, C. Mascaux, B. Lacarelle, F. Barlesi, D. Barbolosi and S. Benzekry, * = equal contribution
    CPT Pharmacometrics Syst Pharmacol, Volume 7, Issue 1, pp. 42-50, hal, 2018

  30. Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach
    M. Benguigui, D. Alishekevitz, M. Timaner, D. Shechter, Z. Raviv, S. Benzekry*, Y. Shaked*, * = joint senior authors
    Oncotarget, Volume 9, pp.2574-2590, 2018

  31. Pharmacokinetics of nanoparticles in oncology: clues for anticipating interpatient variability
    R. Fanciullino, S. Benzekry, B. Lacarelle, J. Ciccolini, A. Rodallec
    Critical Reviews in Oncology/Hematology, Volume 129, pp. 1-12, hal, 2018


    32. 2017



  32. Mathematical modeling of tumor-tumor distant interactions supports a systemic control of tumor growth
    S. Benzekry, C. Lamont, D. Barbolosi, L. Hlatky, P. Hahnfeldt
    Cancer Research, Volume 77, Issue 18, pp.5183-5193, 2017

  33. Non-Standard Radiotherapy Fractionations Delay the Time to Malignant Transformation of Low-Grade Gliomas
    A. Henares-Molina, S. Benzekry, P.C. Lara, M. Garcia-Rojo, V.M. Perez-Garcia and A. Martinez-Gonzalez
    PLoS One, Volume 12, Issue 6, e0178552, hal, 2017

  34. Model Driven Optimization of Antiangiogenics + Cytotoxics Combination: Application to Breast Cancer Mice Treated with Bevacizumab + Paclitaxel Doublet Leads to Reduced Tumor Growth and Fewer Metastasis
    S. Mollard, J. Ciccolini, D.C. Imbs, R. El Cheikh, D. Barbolosi, S. Benzekry
    Oncotarget, Volume 5, 10.18632/oncotarget.15484, 2017


    35. 2016



  35. In vivo bioluminescence tomography for monitoring breast tumor growth and metastatic spreading: comparative study and mathematical modeling
    S. Mollard, R. Fanciullino, S. Giacometti, C. Serdjebi, S. Benzekry, J. Ciccolini
    Scientific Reports, Volume 6, pp.36173, 2016

  36. Mathematical modeling of cancer immunotherapy and synergy with radiotherapy
    R. Serre, S. Benzekry, L. Padovani, C. Meille, N. André, J. Ciccolini, F. Barlési, X. Muracciole, and D. Barbolosi
    Cancer Research, Volume 76, Issue 17, pp. 4931–40, 10.1158/0008-5472.CAN-15-3567, 2016

  37. Modeling spontaneous metastasis following surgery: an in vivo-in silico approach
    S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi, J.M.L. Ebos
    Cancer Research, Volume 76, Issue 3, pp. 535-547, 10.1158/0008-5472.CAN-15-1389, 2016


    38. 2015



  38. Computational modelling of metastasis development in renal cell carcinoma
    E. Baratchart, S. Benzekry*, A. Bikfalvi*, T. Colin*, L.S. Cooley, R. Pineau, E. Ribot, O. Saut, W. Souleyreau, * = joint supervising authors
    PLoS Computational Biology, Volume 11, Issue 11, e1004626, hal, 2015

  39. Metronomics reloaded: theoretical models bringing chemotherapy into the era of precision medicine
    S. Benzekry+, E. Pasquier+, D. Barbolosi, B. Lacarelle, F. Barlesi, N. Andre and J. Ciccolini
    Seminars in Cancer Biology, Volume 35, pp. 53-61, 10.1016/j.semcancer.2015.09.002, 2015

  40. Design Principles for Cancer Therapy guided by changes in complexity of Protein-Protein Interaction Networks
    S. Benzekry , J.A. Tuszynski, E.A. Rietman, G.L. Klement
    Biology Direct, Volume 10, Issue 32, 2015

  41. Host Age is a Systemic Regulator of Gene Expression Impacting Cancer Progression
    A. Beheshti, S. Benzekry, J.T. MacDonald, L. Ma, M. Peluso, P. Hahnfeldt, L. Hlatky
    Cancer Research, Volume 75, Issue 6, pp. 1134-43, 2015


    42. 2014



  42. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth
    S. Benzekry, C. Lamont, A. Beheshti, A. Tracz, J.M.L. Ebos, L. Hlatky, P. Hahnfeldt
    PLoS Computational Biology, Volume 10, Issue 8, e1003800, 2014

  43. Global Dormancy of Metastases due to Systemic Inhibition of Angiogenesis
    S. Benzekry, A. Gandolfi, P. Hahnfeldt
    PLoS One, Volume 9, Issue 1, e84249, 2014



    44. 2013



  44. Maximum Tolerated Dose Versus Metronomic Scheduling in the Treatment of Metastatic Cancers
    S. Benzekry, P. Hahnfeldt
    Journal of Theoretical Biology, Volume 335, pp. 235-244, 2013


  45. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice
    F. Lignet, S. Benzekry, S. Wilson, F. Billy, O. Saut, M. Tod, B. You, A. Adda Berkane, S. Kassour, M.X. Wei, E. Grenier, B. Ribba
    Journal of Theoretical Biology, Volume 320, pp. 86-99, 2013


    46. 2012



  46. Modelling the impact of anticancer agents on metastatic spreading
    S. Benzekry, N. André, A. Benabdallah, J. Ciccolini, C. Faivre, F. Hubert and D. Barbolosi
    Mathematical Modeling of Natural Phenomena , Volume 7, Issue 1, pp. 306 - 336, 2012

  47. A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
    S. Benzekry, G. Chapuisat, J. Ciccolini, A. Erlinger and F. Hubert
    Comptes Rendus de l'Académie des Sciences - Mathématiques, Volume 350, Issue 1-2, pp. 23-28, 2012

  48. Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers
    S. Benzekry
    ESAIM: Mathematical Modelling and Numerical Analysis, Volume 46, Issue 2, pp. 207-237, hal, 2012.


    49. 2011



  49. Passing to the limit 2D-1D in a model for metastatic growth
    S. Benzekry
    Journal of Biological Dynamics, Volume 6, Suppl. Issue 1, pp. 19-30, hal, 2011

  50. Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis,
    S. Benzekry
    Journal of Evolution Equations Volume 11, Issue 1, pp. 187-213, hal, 2011

Book chapters, editorials, proceedings and protocols


  1. Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial. Slides
    F. Barlesi, et al., S. Benzekry
    Annals of Oncology, 16 (suppl_1), 2022

  2. Supporting decision making and early prediction of survival for oncology drug development using a pharmacometrics-machine learning based model.
    S. Benzekry, M. Karlsen, A. El Kaoutari, R. Bruno, A. Neubert, F. Mercier, M. Stern, B. Gomes, S. Vatakuti, P. Curle and Candice Jamois.
    PAGE 30, Abstr 10276, 2022

  3. Abstract LB120: Comprehensive biomarkers analysis to explain resistances to PD1-L1 ICIs: The precision immuno-oncology for advanced non-small cell lung cancer (PIONeeR) trial
    L. Greillier et al., S. Benzekry, J. Fieschi, F. Barlesi
    Cancer Res, 82 (12_Supplement): LB120, 2022

  4. Abstract 2737: A mechanistic model for prediction of metastatic relapse in early-stage breast cancer using routine clinical features
    C. Bigarré, P. Finetti; F. Bertucci; X. Muracciole, S. Benzekry
    Cancer Res, 82 (12_Supplement): 2737, 2022

  5. Abstract 3195: Hijacked senescence secretomes as 'immune primers' of antiangiogenic TKI efficacy
    M. Dolan, Y. Shi, J. W. Hill, M. Mastri, C. Vaghi, J. Barbi, S. Benzekry, J. M. Ebos
    Cancer Res, 81 (13_Supplement): 3195, 2021

  6. Mechanistic models for hematological toxicities: Small is beautiful
    L. Deyme, S. Benzekry, J. Ciccolini
    CPT: Pharmacometrics Syst Pharmacol, Volume 10, Issue 5, pp. 396-398, 2021

  7. Abstract 5493: Mathematical modeling of antibody nanoconjugates transport quantifies the impact of the tumor microenvironment on drug penetration
    C. Vaghi, A. Rodallec, G. Sicard, F. Correard, R. Fanciullino, J. Ciccolini, C. Poignard, S. Benzekry
    Cancer Res, 80 (16_Supplement): 5493, 2020

  8. Abstract 6244: Turning poorly vascularized tumors into highly vascularized tumors with nanoparticles: Proof of concept and pharmacometric analysis
    G. Sicard, A. Rodallec, F. Correard, C. Vaghi, C. Poignard, J. Ciccolini, S. Benzekry, A. Sergé, R. Fanciullino
    Cancer Res, 80 (16_Supplement): 6244, 2020

  9. Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: the PIONeeR and QUANTIC joint-projects
    J. Ciccolini, S. Benzekry, F. Barlesi
    British Journal of Cancer, 2020

  10. Prédiction de l’efficacité de l’immunothérapie dans le cancer bronchique à partir de données cliniques et biologiques simples : apport de l’intelligence artificielle
    M. Grangeon, S. Benzekry, S. Chaleat, P. Tomasini, D. Barbolosi, F. Barlesi, L. Greillier
    Revue des Maladies Respiratoires, Volume 12, Issue 1, pp. 217, hal, 2020

  11. Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess
    J. Ciccolini, N. Andre, D. Barbolosi, S. Benzekry, F. Barlesi
    Annals of Oncology, Volume 62, Issue 2, hal, 2019

  12. Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor.
    C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, J. ML Ebos, C. Poignard and S. Benzekry
    In G. Bebis, T. Benos, K. Chen, K. Jahn, & E. Lima (Eds.), (pp. 87–97). Presented at the Mathematical and Computational Oncology, Cham: Springer International Publishing, 2019

  13. Abstract 4264: Mathematical modeling of differential effects of Sunitinib on primary tumor and metastatic growth.
    C. Nicolo, M. Mastri, J. ML Ebos, S. Benzekry
    Cancer Research, Volume 78, Issue 13 (Supplement), 4264, 2018

  14. Etude de l’effet séquence bevacizumab/pemetrexed/cisplatine chez la souris porteuse de cancer du poumon non à petites cellules.
    A. Boyer, J. Ciccolini, C. Mascaux, D.C. Imbs, R. El Cheikh, F. Barlesi, and S. Benzekry
    Revue des Maladies Respiratoires, 34:A52, 2017

  15. Abstract 4529: Optimization of the sequence for the administration of bevacizumab in combination with pemetrexed and cisplatin in NSCLC : a pharmacology based in vivo study A., Boyer, D.C. Imbs, R.E. Cheikh, C. Mascaux, F. Barlesi, D. Barbolosi, S. Benzekry, and J. Ciccolini.
    Cancer Research, Volume 77, Issue 13 (Supplement), 4529, 2017

  16. Optimized radiotherapy protocols delay the malignant transformation of low-grade gliomas in-silico
    A. Henares-Molina, S. Benzekry, P. Lara, M. García-Rojo, V. Pérez-García, and A. Martínez-González
    Neuro-Oncology, 19 (suppl 3):iii12–iii12, 2017

  17. Les lois de la croissance tumorale
    S. Benzekry
    Bibliothèque Tangente, Hors-série Maths et Médecine, 2016

  18. Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai.
    Pantziarka, P., Hutchinson, L., André, N., Benzekry, S., Bertolini, F., Bhattacharjee, A., et al.
    ecancermedicalscience, 10, 2016

  19. On the growth and dissemination laws in a mathematical model of metastatic growth
    S. Benzekry, J. ML Ebos
    ITM Web of Conferences, Volume 5, 10.1051/itmconf/20150500007, 2015

  20. Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support
    J. Ciccolini, S. Benzekry, B. Lacarelle, D. Barbolosi and F. Barlési
    Proc Natl Acad Sci USA, Volume 112, Issue 27, 10.1073/pnas.1506689112, 2015

  21. Capturing the Driving Role of Tumor-Host Crosstalk in a Dynamical Model of Tumor Growth
    S. Benzekry, A. Beheshti, P. Hahnfeldt, L. Hlatky
    bio-protocol, Volume 5, Issue 21, e1644, hal, 2015

  22. Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxic modalities: application to the bevacizumab-paclitaxel association in breast cancer models S. Mollard, S. Benzekry, S. Giacometti, C. Faivre, F. Hubert, J. Ciccolini and D. Barbolosi.
    Cancer Research, Volume 74, Issue 19 (Supplement), 3677, 2014

  23. A Mathematical Model for Growing Metastases on Oncologists’s Service
    D. Barbolosi, A. Benabdallah, S. Benzekry, J. Ciccolini, C. Faivre, F. Hubert, F. Verga, B. You
    In Computational Surgery and Dual Training, Springer New York, pp. 331-338, 2014

  24. A mathematical model of systemic inhibition of angiogenesis in metastatic development
    S. Benzekry, A. Gandolfi, P. Hahnfeldt
    ESAIM: Proceedings, Volume 45, pp. 75-87, 2014

Foreign research visits

Fall 2016. Short sabbatical at the Roswell Park Cancer Institute to work with John ML Ebos, Buffalo, NY, USA.

September 2015. Invited researcher in the Môlab to work with Alicia Martinez-Gonzalez and Victor Pérez-Garcia, Ciudad Real, Spain.

January 2012 - November 2012. Postdoc at the Center of Cancer and Systems Biology, Boston, USA.

May 2011. Instituto di Analisi dei Sistemi ed Informatica ''Antonio Ruberti'', Consiglio Nazionale delle Ricerche. Research visit with Alberto Gandolfi and collaboration with Alberto d'Onofrio, from the European Institute of Oncology from Milan. Rome, Italy.

March - June 2007. Master 2’s intership in the mathematical department of the Polytechnical University of Catalonia : Exploration of deterministics and stochastics neuronal reds. Barcelona, Spain.


Invited talks


  1. September, 2024. Twelfth International Workshop on Pharmacodynamics of Anticancer Agents. "Use of machine learning for predicting cancer outcomes", Ponta Delgada, Portugal.

  2. July, 2024. ECMTB congress (European Conference on Mathematical and Theoretical Biology). "Mechanistic learning for metastasis modeling and prediction", talk within the mini-symposium "Mechanistic learning in mathematical oncology" organized by A. Kohn-Luque and S. Haupt, Toledo, Spain.

  3. July, 2024. ECMTB congress (European Conference on Mathematical and Theoretical Biology). "Integrating kinetics and machine learning modeling for prediction of outcome following immunotherapy in lung cancer", talk within the mini-symposium "Digital twins for clinical oncology and cancer research" organized by G. Lorenzo, Toledo, Spain.

  4. July, 2024. SMB congress (Society of Mathematical Biology). "Integrative kinetics and machine learning modeling for prediction of outcome following immunotherapy in lung cancer". Talk within the mini-symposium "Mathematical modeling of cancer treatment" organized by E. Kim, Seoul, Korea.

  5. June, 2024. BIOMAT summer school. Mini-course "Mechanistic learning to predict response and survival in immuno-oncology.", Granada, Spain.

  6. March, 2024. Keynote invited speaker in the session "Machine Learning for Rare Disease Applications: from Limited to In Silico Trials" of the Applied machine learning days (AMLD2024), "Mechanistic learning to predict the results of clinical trials", EPFL, Lausanne.

  7. January, 2024. EORTC-PAMM, The PIONeeR trial, Marseille.

  8. October, 2023. Workshop for young researchers in Cancer, invited as keynote speaker, Cancéropôle PACA, Porquerolles.

  9. July, 2023. SMB congress (Society of Mathematical Biology). Talk within the mini-symposium "modeling approaches used to study cancer treatment." organized by K. Wilkie and G. Powathil. L. Nguyen et al., S. Benzekry, Mechanistic modeling of the longitudinal tumor and biological markers combined with quantitative cell-free DNA. Ohio State University, OH, USA.

  10. June, 2023. Annual meeting of the APHM center for early phase clinical trials in oncology, Marseille, France.

  11. June, 2023. Annual congress of the French group of clinical pneumo-oncology (GPCO), Toulon, France.

  12. June, 2023. Annual congress of the French society of pharmacology and therapeutics (SFPT), Limoges, France.

  13. May, 2023. SMAI congress (French Society of Applied and Industrial Mathematics). Talk within the mini-symposium "Modélisation Mathématique du cancer et de son environnement" organized by F. Hubert and M. Mezache. Pointe à Pitre, France.

  14. January, 2023. CARe graduate school workshop, Numerical and technical tools to better investigate metabolism, inflammation and cancer. Toulouse, France.

  15. May, 2022. 8th international conference on Systems Biology of Mammalian Cells: From Systems Medicine towards Digital Health, Heidelberg, Germany

  16. April, 2022. Quantitative systems pharmacology conference, Leiden, The Netherlands

  17. March, 2022. MI Day " Immunotherapies & Lung Cancer : predictive biomarkers from The PIONeeR Project ", Marseille, France

  18. January, 2022. Workshop on tissue growth and movement. Poincaré institute, Paris, France

  19. October, 2021. Multidisciplinary Approaches in Cancer Research. Sophia Antipolis, France

  20. June, 2021. Annual seminar of the regional Canceropole Provence-Alpes Cote d'Azur. COMPO: COMPutational pharmacology and clinical Oncology.

  21. June, 2021. Mini-symposium "Mathematical approaches to advance clinical studies in oncology", Society of Mathematical Biology annual Conference.(online). Quantitative modeling of metastasis: cancer at the organism scale. (Slides)

  22. December, 2020. Workshop on Mathematical modelling in the machine learning era. Göteborg, Sweden (online conference).

  23. May, 2020, CIMPA Research Summer School on Mathematical models applied to molecular dynamics and oncology. Santiago de Cuba, Cuba.

  24. April 2020, 10th European Lung Cancer Congress (ELCC). Geneva, Switzerland.

  25. January, 2020, Second philosophy of cancer workshop. Quantitative modeling of metastasis: cancer at the organism scale. Bordeaux, France. (Slides)

  26. July 2019, International Society of Pharmacometrics (ISoP) workshop. Paris, France. (Slides)

  27. May 2019, Masterclass Mathematiques appliquees CEPS Mathematiques Des Sciences du Vivant, CIRM, Marseille, France. Data-driven mechanistic modeling of metastasis: cancer at the organism scale.

  28. May 2019, NCI Mathematical Oncology Meeting, Portland, USA. Machine learning versus mechanistic modeling for prediction of metastatic relapse in breast cancer.(Slides)

  29. May 2019, RITS conference (Recherche en Imagerie et Technologies pour la Sante) of the French Society of Biomedical Engineering (SFGBM), Tours, France. Data-driven mechanistic modeling of metastasis: cancer at the organism scale. (Slides)

  30. November 2018, Mathematical Challenges in the Analysis of Continuum Models for Cancer Growth, Evolution and Therapy, Oaxaca, Mexico. (Slides)

  31. July 2018, Mathematical perspectives in the biology and therapeutics of cancer, Marseille, France. (Slides)

  32. July 2018, Annual Workshop on Mathematics in Medicine, Wolfgang Pauli Institute, Vienna, Austria. (Slides)

  33. June 2018, 3rd Mathematical Biology Modelling Days, Besançon, France. (Slides)

  34. February 2018, CMM-Fields-Inria Workshop on Mathematics for Medicine, Toronto, Canada.

  35. January 2018, Conference on Statistics and Health, Toulouse, France.

  36. December 2017, Mathematical methods and modeling of biophysical phenomena. Mathematical modeling and prediction of metastasis. Rio de Janeiro, Brazil.

  37. September 2017, Première session du GDR MAMOVI. Mathematical Modeling and Prediction of Clinical Brain Metastases in Non-Small Cell Lung Cancer. Lyon, France

  38. June 2017, XXV Congreso de ecuaciones diferenciales y aplicaciones / XV congreso de matematica aplicada, Optimization of the timing of sequential administration of bevacizumab plus cytotoxics in non-small cell lung cancer by a mathematical model. Cartagena, Spain.

  39. May 2016, Metronomics @ Mumbai. Mathematical modeling of chemotherapy scheduling. Mumbai, India.

  40. December 2015, Present challenges of mathematics in oncology and biology of cancer. Marseille, France.

  41. November 2015, Dynamique et contrôle des croissances tumorales, Rouen, France.

  42. November 2015, Contrôle des EDP et applications , Marseille, France.

  43. October 2015, Journées du Groupe de Métabolisme et Pharmacocinétique , Paris, France.

  44. June 2015, Micro and Macro Systems in Life Sciences (MMSLS 2015), Bedlewo, Poland.

  45. March 2015, Workshop on hybrid and multiscale modelling in cell and cell population biology , Laboratoire Jacques-Louis Lions. Combined in vivo and in silico quantitative modeling of post-surgery metastatic development. Paris, France.

  46. March 2015, Mathematical Methods and Modeling of Biophysical Phenomena, Cabo Frio, Rio de Janeiro, Brazil.

  47. January 2015, 36th EORTC PAMM Winter meeting , Marseille, France.

  48. October 2014, Autumn School by Japanese and French Mathmaticians . Mathematical modeling of tumor growth and metastatic spread. Data, theories and predictions. Osaka, Japan.

  49. July 2014, 10th AIMS Conference on Dynamical Systems, Differential Equations and Applications . A mathematical model of systemic inhibition of angiogenesis in metastatic development. Madrid, Spain.

  50. November 2013, French-Mexican Meeting on Industrial and Applied Mathematics, Villahermosa, México. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth

  51. May 2013, Bi-annual congress of the SMAI. Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics. Seignosse, France.

  52. March 2013, Workshop on Mathematical Methods and Modeling of Biophysical Phenomena, Cabo Frio, Brazil. Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics

  53. July 2012, 2nd Annual Workshop on Cancer Systems Biology — Tumor Metronomics: Timing and Dose Level Dynamics, Center for Cancer and Systems Biology, Boston. Mathematical modeling of metastatic development and scheduling optimization of anti-cancerous therapies

  54. March 2012, Thematic school : "Present challenges of mathematics in oncology and biology of cancer", CIRM, Marseille. A modeling approach for therapies in metastatic cancers

  55. October 2011, Journées du Groupe de Métabolisme et Pharmacocinétique. Paris. Poster and Oral communication, Biomathematical modeling for description of metastatic processes and optimization of combined anti-angiogenic + cytotoxic therapies.

  56. July 2011, Workshop on Systems Biology of Tumor Dormancy. St. Elizabeth's Medical Center, Boston USA. A modelling approach for therapies in metastatic cancers.

  57. July 2011, 7th Congrès International Congress on Industrial and Applied Mathematics - ICIAM 2011, Vancouver. Mathematical modeling of the metastatic process and optimization of anti-cancerous therapies.

  58. May 2011, ``Emergence'' day of the Institut Gustave Roussy (IGR).Un exemple de modélisation du processus métastatique. Paris, France.

  59. June 2010, CANUM 2010, A model of metastatic growth under angiogenic control. Gironde, France.

  60. May 2010, AIMS Dresde. Modeling and mathematical analysis of metastatic growth under angiogenic control. Dresden, Germany

  61. March 2010, 2nd Workshop on Metronomic Anti-Angiogenic Chemotherapy in Paediatric Oncology. Mathematical modeling of MTD and metronomic temozolomide. Marseille, France.

Seminars (invited)


  1. April, 2025. Mechanistic learning for predicting resistance and survival in immune-checkpoint inhibition therapy. Center for Computational Oncology, UT Austin, Texas, USA.

  2. March, 2024. Mechanistic learning for clinical cancer research. CANSEARCH, Geneva University, Switzerland.

  3. May, 2023. Séminaire : Modélisation numérique et application en médecine clinique. Ajaccio, France.

  4. January, 2023. EMD Serono, Cambridge, MA USA. Invited by I. Kareva.

  5. February, 2022. Seminar in the bioinformatics group of the CRCM.

  6. October, 2021. Seminar at the Center for Cancer Research of Marseille. Mechanistic learning : combining mechanistic modeling and statistical learning to predict outcome in clinical oncology. Marseille, France

  7. June 2021, Seminar at the Centre de recherches en cancérologie de Toulouse (CRCT). Quantitative modeling of metastasis: cancer at the organism scale.

  8. May 2021, Seminar at the pharmacometrics group of Merck. COMPO - COMPutational pharmacology and clinical Oncology: Optimization of therapeutic strategies by mechanistic and statistical modeling.

  9. Apr 2021, Seminar of the Pharma - Informatics Unit of the Athena research group, Athens, Greece. COMPO - COMPutational pharmacology and clinical Oncology.

  10. Mar 2021, Applied statistics seminar of the mathematics department. Marseille, France. COMPO - COMPutational pharmacology and clinical Oncology.

  11. Jan 2021, Biomathematics seminar of the mathematics department. Marseille, France. COMPO - COMPutational pharmacology and clinical Oncology.

  12. June 2019, Seminar in the Novartis pharmacometrics department. Basel, Switwerland. Artificial intelligence and machine learning in oncology: myths and reality.

  13. May 2019, Biomedicum Helsinki Seminar (Invitation by Sampsa Hautaniemi), Faculty of Medicine, Helsinki, Finland.

  14. May 2019, Seminaire phases I en oncologie, Marseille, France. Old concept, new name? l’intelligence artificielle en oncologie.

  15. November 2018, Probability and Statistics seminar, Institut Elie Cartan de Lorraine, Nancy, France.

  16. February 2018, Seminar at the Roswell Park Cancer Institute (Invitation by Dr. J. Ebos), Buffalo, USA.

  17. December 2017, Seminar at the Rappaport Faculty of Medicine of the Technion Israel Institute of Technology (invitation by Yuval Shaked). Contributions in Mathematical Oncology: When Theory Meets Reality. Haifa, Israel.

  18. May 2017, Laboratoire d'Analyse Topologie et Probabilites, Institut de Mathematiques de Marseille. Mathematical Oncology: Theory Meets Reality. Marseille, France.

  19. November 2016, Integrated Mathematical Oncology Department, Moffitt Cancer Center.Mathematical Modeling of Metastasis: Theory Meets Reality. Tampa, Florida, USA.

  20. October 2016, Department of Genetics, Roswell Park Cancer Institute (invitation by John ML Ebos). Mathematical Modeling of Metastasis: Theory Meets Reality. Buffalo, NY, USA.

  21. October 2016, Robert Kerbel's laboratory at Sunnybrook Research Institute. Mathematical Modeling of Metastasis: Theory Meets Reality. Toronto, Canada.

  22. October 2016, Mathematics Department Colloquium, Ryerson University. Mathematical Modeling of Metastasis: Predicting the invisible. Toronto, Canada.

  23. May 2016, Seminar at the laboratory of Génétique, Immunothérapie, Chimie et Cancer of the University of Tours. Data-based mathematical modeling analysis of preclinical studies in oncology. Tours, France.

  24. January 2016, Seminar at the laboratoire d'imagerie biomédicale. Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. Paris, France.

  25. March 2014, Seminar at the Inria team Dracula. Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. Lyon, France.

  26. April 2013, Seminar of the ANEDP team . Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics. Orsay, France.

  27. February 2013, Seminar of the LATP, Marseille, France. A math walk in a biology lab

  28. November 2011, EDP seminar of the mathematics lab in Besançon. Modélisation et analyse mathématique de thérapies anti-cancéreuses pour les cancers métastatiques

  29. May 2011, Seminar at the Instituto di Analisi dei Sistemi ed Informatica ``Antonio Ruberti'', Rome. A modelling approach for the metastatic process.

  30. May 2010, Seminar Maths-Bio of the university Lyon 1. Modeling and mathematical analysis of metastatic growth under angiogenic control. Lyon, France

Accepted oral communications


  1. September 2024, ESMO, Paris, France. Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker.
    Salas, S., Nguyen-Phuong, L., Ginot, F., Greillier, L., Tomasini, P., Boutonnet, A., Deville, J.L., Fina, F. and Benzekry, S.
    ESMO, Ann. Oncol., 35, S270, Poster, 2024.

  2. July 2024, Control release society, Bologna, Italy. PK/PD modelling to advance the preclinical development of a novel polymer prodrug in oncology
    A. Rodallec, R. Lee, S. Marolleau, S. Benzekry*, J. Nicolas*, * = joint senior authors
    CRS, Poster, 2024.

  3. June 2024, PAGE, Roma, Italy. Mechanistic modelling of tumor kinetics coupled with biomarker dynamics for survival prediction in non-small cell lung cancer patients
    R. Taieb, R. Bruno, J. Jin, P. Chanu, S. Benzekry
    PAGE, 32, Abstr 10812, Oral, 2024.

  4. June 2024, PAGE, Rome, IT. Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors
    L. Nguyen Phuong, F. Fina, L. Greillier, C. Gaudy-Marqueste, J.L. Deville, J.C. Garcia, S. Salas, S. Benzekry
    PAGE, 32, Abstr 11111, Poster, 2024

  5. June 2024, ASCO, Chicago, USA. Long cell-free DNA fragments predict early-progression in patients with advanced or metastatic cancer treated with immune-checkpoint inhibition
    Salas, S., Phuong, L.N., Garcia, J.-C., Greillier, L., Gaudy-Marqueste, C., Deville, J.-L., Boutonnet, A., Ginot, F., Fina, F., and Benzekry, S.
    ASCO, J. Clin. Oncol., 42, e14550–e14550, Abstract, 2024.

  6. June 2024, ASCO, Chicago, US. Mathematical modelling of routine biological parameters kinetics in order to predict durable benefit for first-line immunotherapy in metastatic or unresectable melanoma
    J. Forestier, A. Daumas, C. Gaudy-Marqueste, S. Benzekry*, N. Malissen*, * = joint senior authors
    ASCO, J. Clin. Oncol., 42, e21549–e21549, 2024

  7. June 2024, JOBIM, Toulouse, FR. Immune landscapes and metabolic profiles in Neuroblastoma
    H. Hamdache, V. Pancaldi* and S. Benzekry*, * = joint senior authors
    JOBIM, 2024

  8. November 2023, SITC, Paris, France. Regulatory T-cell tumor infiltration improves advanced NSCLC patients’ outcome under ≥ 2nd line anti-PD1/L1 monotherapy in The PIONeeR Project. Poster
    M. Landri, ..., S. Benzekry, ..., J. Fieschi
    Journal for ImmunoTherapy of Cancer 11, A1813–A1813, 2023

  9. December 2022, ESMO-IO, Geneva, Switzerland. Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial. Oral
    F. Barlesi, et al., S. Benzekry
    ESMO IO, Abstr 3MO, 2022

  10. June 2022, 30th population approaches group in Europe (PAGE) conference, Ljubljana, Slovenia. Supporting decision making and early prediction of survival for oncology drug development using a pharmacometrics-machine learning based model. Oral
    S. Benzekry, M. Karlsen, A. El Kaoutari, R. Bruno, A. Neubert, F. Mercier, M. Stern, B. Gomes, S. Vatakuti, P. Curle and Candice Jamois.
    PAGE 30, Abstr 10276, 2022

  11. April 2022, AACR conference, New Orleans, USA. Comprehensive biomarkers analysis to explain resistances to PD1-L1 ICIs: The precision immuno-oncology for advanced non-small cell lung cancer (PIONeeR) trial. Poster
    L. Greillier, ..., S. Benzekry, J. Fieschi, F. Barlesi.
    AACR, Abstr LB120, 2022

  12. April 2022, AACR conference, New Orleans, USA.A mechanistic model for prediction of metastatic relapse in early-stage breast cancer using routine clinical features
    C. Bigarré, P. Finetti, F. Bertucci, X. Muracciole, S. Benzekry
    AACR, Abstr. 2737, 2022

  13. March 2022, World conference on pharmacometrics (WCOP), Cape Town, South Africa.
    Pharmacometrics modeling coupled with machine learning for early prediction of overall survival following atezolizumab monotherapy in non-small cell lung cancer. Poster
    S. Benzekry, M. Karlsen, A. El Kaoutari, S. Vatakuti, P. Curle and Candice Jamois

  14. March 2022, World conference on pharmacometrics (WCOP), Cape Town, South Africa.
    Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data. Poster
    S. Benzekry, M. Grangeon, M. Karlsen, M. Alexa, I. Bicalho-Frazeto, S. Chaleat, P. Tomasini, D. Barbolosi, F. Barlesi, L. Greillier

  15. July 2021, AACR, online, US.
    Hijacked senescence secretomes as 'immune primers' of antiangiogenic TKI efficacy. Poster
    M. Dolan, Y. Shi, J.W. Hill, M. Mastri, C. Vaghi, J. Barbi, S. Benzekry, J. M.L. Ebos
    16. Cancer Res, 81 (13_Supplement):3195, 2021

  16. December 2020, Workshop on cancer adaptive therapy models. Examples of pharmacometrics studies in preclinical and clinical oncology: mathematical models in concrete therapeutic applications. Moffitt Cancer Center, Tampa, Florida, USA (online conference). (Slides). (Youtube video)

  17. August 2020, Virtual Physiological Human 2020 (VPH2020), Paris, France. Descriptive and prognostic value of a computational model of metastasis in high-risk neuroblastoma. Oral

  18. June 2019, Population Approach Group meeting in Europe (PAGE), Stockholm, Sweden. Machine learning versus mechanistic modeling for prediction of metastatic relapse in breast cancer. Oral

  19. June 2019, Population Approach Group meeting in Europe (PAGE), Stockholm, Sweden. Machine learning combined to mechanistic modeling of differential effects of neo-adjuvant Sunitinib on primary tumor and metastatic growth. Oral (senior author, first author and speaker C. Nicolo)

  20. August 2018, 17th Biennial Congress of the Metastasis Research Society, Princeton, NJ, USA. A biologically-based mathematical model for prediction of metastatic relapse. Poster.

  21. July 2018, Mathematical perspectives in the biology and therapeutics of cancer, Marseille, France. Improving intra-tumor drug distribution of anti-cancer nanoparticles by data-informed mathematical modeling. Oral (senior author, first author C. Vaghi).

  22. June 2018, Data science summer school, Polytechnique, Palaiseau, France. Improving intra-tumor drug distribution of anti-cancer nanoparticles by data-informed mathematical modeling. Poster (senior author, first author C. Vaghi. Won the best poster award)

  23. June 2018, Data science summer school, Polytechnique, Palaiseau, France. Poster

  24. May 2018, Population Approach Group in Europe (PAGE) meeting, Montreux, Switzerland. Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin. Poster (co-senior author with J. Mochel, first author B. Schneider).

  25. April 2018, Annual meeting of the AACR, Chicago, USA. Mathematical modeling of differential effects of Sunitinib on primary tumor and metastatic growth. Poster (senior author, first author C. Nicolo).

  26. March 2017, 38th EORTC-PAMM Winter meeting, Split, Croatia. Optimization of the timing of sequential administration of bevacizumab plus cytotoxics in NSCLC by a mathematical model.

  27. October 2015, Journées du cancéropôle Grand Sud-Ouest , Bordeaux, France. Poster. Modeling spontaneous metastasis following surgery: an in vivo-in silico approach

  28. June 2015, Mathematical Methods in Systems Biology, Dublin, Ireland.

  29. June 2014, European Conference on Mathematical and Theoretical Biology , Göteborg, Sweden. Metastatic dynamics, systemic inhibition of angiogenesis and implications for surgery

  30. June 2014, International Tumor Dormancy Symposium , Lille, France. Metastatic dynamics and systemic inhibition of angiogenesis. Implications for dormancy and surgery (Poster)

  31. February 2014, Demonstration during the inria-industry meeting, Lyon, France. Mathematical Models in Preclinical Cancer Research

  32. January 2014, Seminar at the ISPED. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth. Bordeaux, France.

  33. June 2011, 8th European Conference on Mathematical and Theoretical Biology - ECMTB 2011 and Annual Meeting of The Society for Mathematical Biology, Kraków. Optimal schedules for therapies in metastatic cancers .

  34. May 2010, CMPD 3, Bordeaux. Modeling and mathematical analysis of metastatic growth under angiogenic control.

  35. November 2009, Conference of biomathematics et biomechanics, Tozeur, Tunisie. Presentation of a poster.

  36. August 2009, CEMRACS. Asymptotic behavior of the solutions of the renewal equation and Angiogenesis modeling.

  37. June 2009, Bucolic days of the student's seminar of the LATP.

  38. November 2008, Workgroup Maths-Cancer of Marseille. About the article "A theoretical study of the response of vascular tumours to different types of chemotherapy" de J. Panovska, H. M. Byrne et P. K. Maini.

Participation to conferences and summer schools

6-8 June 2011, Biomat 2011, Perspectives in Mathematics and Life Sciences.

3-4 Février 2011, Journées Louis Antoine "Nonlocal equations and population adaptive dynamics".

2 December 2010. Thematic day "Models and imaging in oncology", Paris, France.

30 November - 1er December 2009. Symposium "Health and complex systems" of the Entretiens Jacques Cartier, Lyon, France.

20-23 November 2009. Conference of biomathématics et biomechanics, Tozeur, Tunisie.

20 July - 28 August 2009. CEMRACS'09 Mathematical modeling in Medicine. Project Angio. CIRM, Marseille, France.

2 - 13 February 2009. Advanced courses and conferences in mathematical biology : modeling and differential equations. CRM, Barcelone, Espagne.

18 - 19 December 2008. Pharmacokinetics and pharmacodynamics of anticancerous drugs : resistances and synergies. Centre de recherche des cordeliers, Paris.